Purchase this article with an account.
Miho Osada, Tsutomu Sakai, Kana Kuroyanagi, Goichi Akiyama, Hideo Kohno, Hiroshi Tsuneoka; Prevention Of Experimental Autoimmune Uveoretinitis By Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2955.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Peroxisome proliferator-activated receptor-α (PPARα) agonist fenofibrate (LIPIDIL®) has been shown to have anti-inflammatory activity and suppress the development of experimental autoimmune encepharomyelitis. In this study, we investigated the effect of PPARα agonist fenofibrate in experimental autoimmune uveoretinitis (EAU).
Lewis rats were immunized with retinal S antigen peptide and the severity of EAU disease was scored. The PPARα agonist fenofibrate (20mg/kg/day) was orally administered every day from day 0 postimmunization until day 14. The eyes were obtained on day 21 postimmunization and the histological score was determined using pathological findings. The expression of inflammatory cytokines including IL-6, IL-17, and VEGF was determined immunohistochemically.
Systemically administered PPARα agonist fenofibrate suppressed the development of EAU. The clinical scores (control:fenofibrate) were 2.83±0.93:1.17±0.98 and 3.67±0.40:1.42±0.86 on day 17 and 21 postimmunization, respectively. PPARα agonist fenofibrate also decreased the histological scores and the expression of inflammatory cytokines in the retina of EAU.
These results suggest that PPARα agonist fenofibrate may modulate the development of EAU and suppress intraocular inflammation by decreasing the production of inflammatory cytokines.
This PDF is available to Subscribers Only